On November 5, CANSINOBIO rose 5.42% in regular trading, trading at HK$27.42, with turnover of HK$37.61 million.

The move aligned with continued strength across Hong Kong biotech stocks, with BEONE MEDICINES up 5.1%, INNOVENT BIO up 4.0%, AKESO up 3.76%, SKB BIO up 5.92%, and 3SBIO up 5.02%.

On the company side, CANSINOBIO reported third-quarter results on October 27 showing revenue of RMB882 million for the first nine months, up 27.40% year over year, while attributable net profit rose 12.82% to RMB16.29 million. Third-quarter revenue was RMB332 million, up 7.17% year over year. These figures provided recent fundamental support to sentiment as the sector advanced.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)